441 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AZN Astrazeneca PLC $37.56 $95.16B N/A
Article Searches
Company News for March 28, 2017 http://www.zacks.com/stock/news/254380/company-news-for-march-28-2017?cid=CS-ZC--254380 Mar 28, 2017 - Companies in the News are: AAPL,GIII,AZN,DIS
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China http://www.zacks.com/stock/news/254215/astrazenecas-lung-cancer-drug-tagrisso-approved-in-china?cid=CS-ZC-FT-254215 Mar 27, 2017 - AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.
AstraZeneca Stock Rising in '17: What's Working in its Favor? http://www.zacks.com/stock/news/253879/astrazeneca-stock-rising-in-17-whats-working-in-its-favor?cid=CS-ZC-FT-253879 Mar 23, 2017 - Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
Infinity Pharma Focuses on Cancer Drug: Competition Looms http://www.zacks.com/stock/news/253597/infinity-pharma-focuses-on-cancer-drug-competition-looms?cid=CS-ZC-FT-253597 Mar 21, 2017 - We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal http://www.zacks.com/stock/news/253385/astrazeneca-azn-gets-another-crl-for-zs-9-inks-copd-deal?cid=CS-ZC-FT-253385 Mar 20, 2017 - London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
AstraZeneca (AZN): Should Value Investors Pick this Stock? http://www.zacks.com/stock/news/253191/astrazeneca-azn-should-value-investors-pick-this-stock?cid=CS-ZC--253191 Mar 17, 2017 - Is AstraZeneca a great pick from the value investor's perspective right now? Read on to know more.
Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded http://www.zacks.com/stock/news/253183/pharma-stock-roundup-astrazenecas-lynparza-impresses-in-study-merck-drug-label-expanded?cid=CS-ZC-FT-253183 Mar 17, 2017 - Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.
Inovio (INO) Q4 Loss Wider than Expected; Shares Decline http://www.zacks.com/stock/news/253047/inovio-ino-q4-loss-wider-than-expected-shares-decline?cid=CS-ZC-FT-253047 Mar 16, 2017 - Inovio Pharmaceuticals, Inc. (INO) reported a loss of 36 cents for the fourth quarter of 2016.
AstraZeneca's Cancer Drug Lynparza Positive in Phase III http://www.zacks.com/stock/news/252915/astrazenecas-cancer-drug-lynparza-positive-in-phase-iii?cid=CS-ZC-FT-252915 Mar 15, 2017 - AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.
How Incyte Stock Became a Bull Market Star for Biotech Investors http://www.zacks.com/stock/news/252365/how-incyte-stock-became-a-bull-market-star-for-biotech-investors?cid=CS-ZC-FT-252365 Mar 10, 2017 - Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

Pages: 1...373839404142434445

<<<Page 42>